Clinical Trial Update: Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039) [Phase 1]

View source ↗

Summary

This Phase 1 study evaluates the pharmacokinetics of Anacetrapib (MK0859) in patients with hepatic insufficiency. Results inform potential dosing considerations…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• Anacetrapib (anacetrapib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Dyslipidemia | Phase 1 | Status: COMPLETED